Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys Buys Sloning BioTechnology for $26.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German biotech firm MorphoSys today announced it has acquired Sloning BioTechnology, which is developing new methods of synthetic biology, for €19 million ($26.5 million).

MorphoSys will now be the sole source for Sloning's Slonomics technology, which enables the precise construction of protein libraries "comprising defined mixtures of amino acids at predetermined positions with unprecedented speed," MorphoSys said in a statement, adding that the technology represents a new and flexible approach for generating optimized proteins, such as antibodies.

Integration of the Slonomics technology in MorphoSys' existing antibody platform is expected to improve the success rate for new drug candidate development to the point where 50 percent of new projects will reach clinical development, MorphoSys said.

The company will also use Sloning's technology to develop therapeutic and diagnostic antibodies.

Sloning was founded in 2001 and is headquartered in Puchheim, Germany.

MorphoSys said the deal is not material to its financial guidance for 2010.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.